Multiple government agencies have taken enforcement action against Cerebral, a major telehealth company, for illegally prescribing controlled substances like ADHD stimulants without requiring in-person medical examinations. The U.S. Department of Justice and Drug Enforcement Administration settled with Cerebral in November 2024 for $3.65 million in forfeited proceeds from controlled substance prescriptions, plus an additional $2.92 million penalty that could be waived if the company remains compliant for 30 months. This represents a total settlement value of $6.57 million from the federal government alone.
Additionally, the Federal Trade Commission (FTC) reached a separate $7 million settlement with Cerebral in April 2024 over data sharing practices and deceptive cancellation policies, affecting more than 40,000 consumers who are entitled to refunds. These cases expose a systematic pattern of regulatory violations that put patient safety at risk and raise critical questions about how telehealth companies are overseen. The enforcement actions reveal that Cerebral executives and business practices directly pushed healthcare providers to prioritize rapid prescription issuance over proper medical evaluation. The company tracked an internal metric called “Initial Visit Rx Rate” to measure how many patients received controlled substance prescriptions during their first telehealth appointment—bypassing the standard medical requirement for in-person examination before prescribing stimulants. This article explains what Cerebral did wrong, how much consumers can recover, who qualifies for compensation, and what changes the company has made in response to regulatory pressure.
Table of Contents
- What Violations Led to the Cerebral Enforcement Action?
- How Much Settlement Money Is Available for Consumers?
- Who Qualifies for the FTC Settlement and How to File a Claim?
- What Regulatory Rules Did Cerebral Violate?
- What Changes Has Cerebral Made Since the Enforcement Actions?
- How Duplicate Accounts and Multiple Prescriptions Put Patients at Risk?
- What Does the Cerebral Case Mean for the Telehealth Industry?
What Violations Led to the Cerebral Enforcement Action?
Between 2021 and 2022, Cerebral operated a business model that systematically violated federal controlled substance prescribing requirements. The company used financial incentives to pressure its contracted healthcare providers to meet stimulant prescribing quotas, and disciplined providers who refused to prescribe enough controlled substances. Rather than following the legal requirement to conduct thorough evaluations and complete in-person examinations before issuing prescriptions for ADHD medications, Cerebral’s internal systems rewarded providers for writing prescriptions quickly on initial telehealth visits. For example, a new patient could contact Cerebral, have a brief video consultation, and receive an ADHD stimulant prescription in a single session—a practice that would normally violate the Ryan Haight Act, which mandates in-person evaluation before controlled substance prescribing.
The company also created operational chaos that compounded the safety risks. Cerebral maintained thousands of duplicate patient accounts, meaning some patients received multiple stimulant prescriptions from different providers within the system—increasing risks of overdose and drug interactions. These weren’t accidental administrative errors; they were documented practices that the Department of Justice identified in its investigation. The enforcement actions show that Cerebral’s leadership knew about these practices: the company’s CEO Kyle Robertson was fired in May 2022 as pressure mounted from regulators and media attention, suggesting awareness of the problems at the executive level.
How Much Settlement Money Is Available for Consumers?
The total compensation from enforcement actions exceeds $10 million, split between two major settlements with different purposes. The DOJ/DEA settlement requires Cerebral to forfeit $3.65 million in proceeds earned from ADHD medication prescriptions—money that regulators identified as coming from unlawful business practices. The company also faces a $2.92 million civil penalty, though this penalty could be waived if Cerebral demonstrates compliance with controlled substance regulations for 30 months following the settlement agreement signed in November 2024. If the company remains compliant during that period, the total federal settlement value could drop to $3.65 million; if Cerebral violates the agreement again, the additional $2.92 million penalty becomes due.
However, this federal settlement differs from consumer compensation in an important way: the forfeited proceeds and penalties go to the government, not directly to patients. The more direct consumer relief comes from the ftc settlement. The FTC determined that Cerebral engaged in deceptive practices around both controlled substance prescribing and account cancellation, and as a result, over 40,000 consumers are entitled to refunds. The $7 million FTC settlement is specifically allocated for consumer refunds, making it the most direct path to compensation for affected patients. Consumers who received prescriptions they shouldn’t have, who were billed for services or subscriptions they couldn’t cancel, or who had their data shared inappropriately with third parties are among those eligible for FTC refund claims.
Who Qualifies for the FTC Settlement and How to File a Claim?
The FTC settlement covers consumers who used Cerebral’s services between certain dates specified in the settlement agreement and experienced any of the alleged violations—receiving controlled substance prescriptions inappropriately, being charged subscription fees they couldn’t cancel, or having their personal health data shared without proper consent. The settlement specifically addresses the deceptive cancellation practices Cerebral employed, where customers found it difficult or impossible to stop their subscriptions. If you created a Cerebral account, received telehealth consultations, were prescribed controlled substances like ADHD stimulants, or paid subscription fees during the period covered by the FTC investigation, you may be eligible for compensation.
To file a claim, affected consumers should watch for official notices from the FTC, which will include a claims process and deadline. It’s crucial to use only official FTC channels for this process—scammers often pose as settlement administrators or claim representatives, asking for payment or personal information to “process your claim.” Legitimate FTC settlements are administered by court-appointed claims administrators, and the process is always free to consumers. Never provide banking information, social security numbers, or payments to third parties claiming to represent a settlement. The official FTC website and any formal legal notices from Cerebral will provide legitimate claims filing information, and you should verify any communications with the official FTC website or consult with a consumer protection attorney.
What Regulatory Rules Did Cerebral Violate?
The federal prohibition against prescribing controlled substances without in-person evaluation comes from the Ryan Haight Act, a 2008 law that requires doctors or other prescribers to conduct face-to-face medical evaluations before issuing prescriptions for controlled substances. During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) temporarily waived the in-person requirement for telehealth to allow patients to access necessary medications during lockdowns. These temporary flexibilities, originally set to expire in 2020, have been repeatedly extended through administrative action and currently remain in effect through December 31, 2025. However, temporary regulatory flexibility does not eliminate the requirement for proper medical evaluation—prescribers still must conduct thorough assessments and determine that controlled substances are medically necessary and appropriate.
Cerebral’s violation wasn’t simply using telehealth to prescribe during the pandemic exemption period; rather, Cerebral created internal systems that incentivized rushing through medical evaluations and prioritized rapid prescription issuance over proper assessment. The company’s business metrics tracked “Initial Visit Rx Rate,” explicitly measuring how many patients received prescriptions during their first appointment. This created a financial incentive structure that pressured providers to prescribe quickly, which violated both the spirit of what the temporary flexibilities were intended to allow and the actual regulatory requirements for medical evaluation. The FTC and DOJ both concluded that Cerebral’s practices crossed the line from “using available regulatory flexibility” into “systematically ignoring the requirement for proper medical assessment.”.
What Changes Has Cerebral Made Since the Enforcement Actions?
Cerebral has made significant operational changes that suggest the enforcement actions had real impact on the company. Most importantly, Cerebral ceased all controlled substance prescribing as of October 15, 2022—roughly a year before the DOJ/DEA settlement was finalized. This means that Cerebral no longer prescribes ADHD stimulants like Adderall, Ritalin, or Concerta, nor does it prescribe other controlled substances. The company now focuses exclusively on non-stimulant ADHD medications, including Strattera (atomoxetine), Wellbutrin (bupropion), and Qelbree (viloxazine)—medications that are not controlled substances and do not trigger the same regulatory restrictions. For patients who need stimulant medications, this means Cerebral is no longer an option, and they must seek prescriptions through traditional in-person medical providers or other telehealth services that maintain proper protocols.
The limitation of Cerebral’s strategy is that many patients find non-stimulant medications less effective for ADHD symptoms than stimulants are. While some patients respond well to Strattera or Wellbutrin, others find these alternatives don’t provide the same symptom relief. By eliminating stimulant prescribing entirely, Cerebral solved its regulatory problem but may have reduced the clinical utility of its service for ADHD patients. For consumers who previously received Cerebral prescriptions for stimulants, the change means losing a convenient access point and potentially facing longer waits or less convenient options through other providers. The company did not return to controlled substance prescribing following the November 2024 settlement, suggesting that exit from this market segment is permanent rather than a temporary compliance measure.
How Duplicate Accounts and Multiple Prescriptions Put Patients at Risk?
One of the most serious findings in the DOJ investigation was that Cerebral maintained thousands of duplicate patient accounts, allowing some individuals to receive multiple controlled substance prescriptions from different providers within the system. This practice creates genuine medical danger: a patient could receive one ADHD stimulant prescription from Provider A, and simultaneously—without either provider knowing—receive a second stimulant prescription from Provider B through a different account in Cerebral’s system. The patient would then have double the prescribed dose without any provider’s knowledge, dramatically increasing risks of overdose, cardiovascular complications, and dangerous drug interactions.
For example, if a patient received two prescriptions for 30mg Adderall daily (one per account), they could accumulate 60mg daily without any medical oversight. The existence of duplicate accounts also suggests inadequate identity verification and patient monitoring systems—problems that go beyond the controlled substance issue specifically. If Cerebral couldn’t prevent the same person from creating multiple accounts and seeing multiple providers, what other patient safety systems might have been inadequate? The enforcement actions didn’t specify whether these duplicate accounts were created intentionally by patients trying to obtain extra prescriptions, or whether they resulted from sloppy account management on Cerebral’s side, but either scenario reveals systemic failures. Regulators would expect a responsible telehealth company to detect duplicate accounts automatically and flag them for investigation, especially when controlled substances are involved.
What Does the Cerebral Case Mean for the Telehealth Industry?
The Cerebral enforcement actions represent a significant regulatory statement about how seriously federal authorities take controlled substance prescribing violations, even during a pandemic when temporary flexibilities are in effect. The DOJ’s decision to pursue both criminal-style forfeiture of proceeds and civil penalties signals that regulators view improper stimulant prescribing as a serious public health threat, not merely a compliance technicality. For other telehealth companies offering controlled substance prescriptions, the message is clear: business model incentives that pressure providers to prescribe quickly will face enforcement action, and executives who create these systems face potential personal accountability. The speed with which Cerebral’s CEO was removed after regulatory pressure became public suggests that Cerebral’s board recognized the severity of the legal exposure.
Looking forward, the extended COVID-era flexibilities for telehealth controlled substance prescribing remain in effect through at least December 31, 2025, and will likely face either renewal or restriction as regulators reassess whether the temporary measures should become permanent. The Cerebral case will likely inform that regulatory decision—suggesting that if telehealth is to retain access to controlled substance prescribing, much stricter oversight and compliance requirements will be expected. Other telehealth companies will need to demonstrate strong systems for preventing duplicate accounts, for ensuring thorough medical evaluation, and for avoiding financial incentives that reward rapid prescribing. The regulatory environment around telehealth prescribing is clearly tightening, and the Cerebral case serves as a cautionary example of what not to do.